GoodMind Therapeutics is able to offer a cutting-edge treatment option utilising a new intranasal medicine, recently registered on the ARTG, for eligible DVA patients facing treatment-resistant symptoms.

This therapy is administered currently only in Sydney, and may be suitable for patients who have tried two or more conventional medications in their current episode of low mood or feelings of despair without experiencing the desired relief.

What is the cost?

The cost of treatment for eligible patients may be covered by the DVA on a case-by-case basis. Our team will discuss details with you.

What is the treatment process?

At this stage, treatment is administered in Sydney. Eligible patients embarking on this journey will undergo a structured screening and treatment program, comprising three essential phases:

Induction Phase:

Over four weeks, patients will engage in 2 sessions per week to initiate their treatment journey.

Maintenance Phase:

Following induction, patients transition to a maintenance phase, attending 1 session per week for 4 weeks to sustain their progress.

Tailored Frequency:

As treatment progresses beyond the initial 8 weeks, the frequency of sessions will be individually tailored, occurring either weekly or fortnightly to accommodate the patient’s evolving needs while ensuring continued therapeutic response.

Under the careful guidance of our qualified medical personnel, patients will receive thorough monitoring throughout the administration of the intranasal medication post-treatment. For the safety and well-being of our patients, driving following treatment sessions is not permitted.

You must complete an initial screening with a Nurse Practitioner, and then a Psychiatrist.